Hooshmandi, 2022 - Google Patents
Dysregulated mRNA Translation in Autism Spectrum DisordersHooshmandi, 2022
View PDF- Document ID
- 6244686648048115157
- Author
- Hooshmandi M
- Publication year
External Links
Snippet
Deviation from the optimal level of proteostasis has been causally associated with a variety of clinical disorders, including autistic phenotypes in fragile X syndrome (FXS). Elevated levels of general protein synthesis have been reported in FXS animal models and patients …
- 108020004999 messenger RNA 0 title abstract description 78
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tai et al. | Tau reduction prevents key features of autism in mouse models | |
| Silva et al. | Inflammation and matrix metalloproteinase 9 (Mmp‐9) regulate photoreceptor regeneration in adult zebrafish | |
| Bowen et al. | The spatiotemporal pattern and intensity of p53 activation dictates phenotypic diversity in p53-driven developmental syndromes | |
| Kleijer et al. | Neurobiology of autism gene products: towards pathogenesis and drug targets | |
| Zhang et al. | Valosin-containing protein (VCP/p97) inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP disease mutants | |
| Won et al. | Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses | |
| Dubos et al. | Conditional depletion of intellectual disability and Parkinsonism candidate gene ATP6AP2 in fly and mouse induces cognitive impairment and neurodegeneration | |
| Zhu et al. | Absence of TRIM32 leads to reduced GABAergic interneuron generation and autism-like behaviors in mice via suppressing mTOR signaling | |
| Bavley et al. | Rescue of learning and memory deficits in the human nonsyndromic intellectual disability cereblon knock-out mouse model by targeting the AMP-activated protein kinase–mTORC1 translational pathway | |
| Nano et al. | Consequences of centrosome dysfunction during brain development | |
| US9125862B2 (en) | Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor | |
| Ma et al. | eEF2 in the prefrontal cortex promotes excitatory synaptic transmission and social novelty behavior | |
| Leone et al. | Understanding copy number variations through their genes: a molecular view on 16p11. 2 deletion and duplication syndromes | |
| Penberthy et al. | Context-dependent compensation among phosphatidylserine-recognition receptors | |
| Ramos-Brossier et al. | Slc20a1 and Slc20a2 regulate neuronal plasticity and cognition independently of their phosphate transport ability | |
| CN111356452A (en) | Methods and compositions for treating neurological conditions | |
| Hooshmandi | Dysregulated mRNA Translation in Autism Spectrum Disorders | |
| US20100112600A1 (en) | Methods and compositions for modulating synapse formation | |
| WO2022047212A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| KR101499299B1 (en) | Autism model mouse by Shank2 gene deletion and the use thereof | |
| Malik | An in vivo study of novel genetic modifiers | |
| Lepagnol-Bestel et al. | AUTS2 gene dosage affects synaptic AMPA receptors via a local dendritic spine AUTS2-TTC3-AKT-mTORC1 signaling dysfunction | |
| Chen et al. | dysregulates dopamine receptor expression and odor preference | |
| Wiebe | Translational control in autism spectrum disorder and memory: a novel role for 4EHP | |
| Saei Arezoumand | A pre-clinical study of a therapy for Rett Syndrome by using a relevant transgenic mouse model |